NRSN Company Profile and Key Details

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) closed at $0.77 USD, gaining $0.06 (8.34%) from the previous close of $0.71. The stock is currently mid-range between its 52-week high and low $0.68 and $2.60. With a market capitalization of about $18.97 million, NeuroSense Therapeutics Ltd. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.56). Key stats such as the average daily volume over the past year has been around 325.80 thousand shares, in line with its 52-week average. Headquartered in Herzliya, None, NeuroSense Therapeutics Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alon Ben-Noon, the company employs approximately 17 people and listed since December 09, 2021. NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases.

NeuroSense Therapeutics Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.18. This means the shares are trading above this model’s fair value.

NeuroSense Therapeutics Ltd. has 24.60 million shares outstanding. The public float is 12.54 million shares, elevated short interest at 2.84% of float. This equals 579.23 thousand shares. The short ratio is 2.55 days. Institutional investors hold 2.56% of the float. Insiders own 29.68%.

NRSN has shown weak momentum, losing -8.45% over the past week and -38.48% over the past quarter, though year-to-date performance is down -35.92%. Short-term trend indicators are bullishly aligned (SMA20 -13.98%, SMA50 -23.58%, SMA200 -41.18%). The stock’s 14-day RSI is 36.34 (weak momentum), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.42% below its high and over 9.84% above its low. Average 10-day trading volume of 306.32 thousand shares is in line with the 3-month average of 312.30 thousand, indicating normal recent market interest.

NeuroSense Therapeutics Ltd. generated EPS of -$0.58 over the past year. Five-year average earnings growth is 2.71%. Wall Street analysts project EPS growth of 24.99% annually over the next five years. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$0.61. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $14.00. The high target offers 1718.18% upside. The low target suggests 1718.18% downside. The mean target is $14.00. This offers 1718.18% upside. NeuroSense Therapeutics Ltd. earnings surprise history is a mixed track record. The quarter that ended December 17, 2025, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include -31.25% in December 18, 2024.

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares are down -35.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows NeuroSense Therapeutics Ltd. trading at a premium to the broader market with a P/E of -2.2. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.70, suggesting 1551.5% upside. Our AI forecast model points to short-term weakness (-24.58% over two weeks), a medium-term fall (-44.08% over three months), and a longer-term gain (1109.36% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that NeuroSense Therapeutics Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -24.58%, with price expected at $0.58 by January 14, 2026, within a range of $0.48 to $0.68 3-Month Outlook: Projected fall of -44.08%, reaching $0.43 by March 30, 2026, with a range of $0.35 to $0.50. 1-Year Outlook: Projected gain of 1109.36%, with price at $9.30 by December 31, 2026, within a range of $6.94 to $13.35.

NeuroSense Therapeutics Ltd. trades at a P/E ratio of -2.2, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -36.64 indicating negative book value, which may reflect financial stress. The P/FCF stands at -9232.73, also below market averages.